RxDoctor Payments DataLook up a doctor →

Jason Mendivil, DPM

Foot & Ankle Surgery · El Paso, TXNPI 1790117893

Payments from drug & device makers

$80,514in general payments, 2019–2025

Across 217 payments — averaging $371.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bone Support Inc.$31K
  • Reapplix Inc.$29K
  • Flower Orthopedics Coporation$6K
  • ETS Wound Care LLC$3K
  • Globus Medical$3K
  • Paragon 28, Inc.$2K
  • plus $7K from 19 others
$60,043in research payments, 2019–2025

Across 4 payments — averaging $15,011 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Reapplix Inc.$60K

What the payments were for

  • Consulting fees$52,40565%
  • Speaking & faculty fees$12,13815%
  • Travel & lodging$10,47113%
  • Food & beverage$5,5007%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,514 in reported general payments places this provider in the 90th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas

Medicare billing

Part B allowed, 2024
$1,531,780
Medicare patients
146
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.33$57,212
Diclofenac Sodium80$3,486
SsdSilver Sulfadiazine56$1,877
Cephalexin37$412
Silver Sulfadiazine12$377
Lidocaine-PrilocaineLidocaine/Prilocaine26$352
Ammonium Lactate11$241
Meloxicam93$232
Clotrimazole14$222
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$208
Acetaminophen-CodeineAcetaminophen With Codeine23$164
Folic Acid20$142
Methylprednisolone23$141
Gabapentin12$86
Ondansetron Hcl12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,057$57,21233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 684 foot & ankle surgery providers in Texas.

Other foot & ankle surgery in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →